Stearyl-norleucine-vasoactive intestinal peptide (VIP): A novel VIP analog for noninvasive impotence treatment

Illana Gozes; Ayelet Reshef; Dalia Salah; Sara Rubinraut; Mati Fridkin

doi:10.1210/en.134.5.2121

Stearyl-norleucine-vasoactive intestinal peptide (VIP): A novel VIP analog for noninvasive impotence treatment

Illana Gozes^*, Ayelet Reshef, Dalia Salah, Sara Rubinraut, Mati Fridkin

^*Corresponding author for this work

Human Molecular Genetics Biochemistry

Research output: Contribution to journal › Article › peer-review

50 Scopus citations

Abstract

The present report relates to pharmaceutical composition for the treatment of male impotence. The transdermal application of a potent derivative of vasoactive intestinal peptide (VIP) coupled to a suitable hydrophobic moiety (e.g. stearyl-VIP) in a suitable ointment composition (e.g. Sefsol) enhances sexual activity and erection formation in a variety of impotence models in rats (sterile rats, diabetic rats, and animals with high blood pressure). Furthermore, exchange of the methionine in position 17 with norleucine enhances biological activity. Thus, stearyl-Nle¹⁷-VIP may be considered useful for the treatment of impotence.

Original language	English
Pages (from-to)	2121-2125
Number of pages	5
Journal	Endocrinology
Volume	134
Issue number	5
DOIs	https://doi.org/10.1210/en.134.5.2121
State	Published - May 1994

Access to Document

10.1210/en.134.5.2121

Cite this

@article{7f23c1a677894274bb8169ab559dcab6,

title = "Stearyl-norleucine-vasoactive intestinal peptide (VIP): A novel VIP analog for noninvasive impotence treatment",

abstract = "The present report relates to pharmaceutical composition for the treatment of male impotence. The transdermal application of a potent derivative of vasoactive intestinal peptide (VIP) coupled to a suitable hydrophobic moiety (e.g. stearyl-VIP) in a suitable ointment composition (e.g. Sefsol) enhances sexual activity and erection formation in a variety of impotence models in rats (sterile rats, diabetic rats, and animals with high blood pressure). Furthermore, exchange of the methionine in position 17 with norleucine enhances biological activity. Thus, stearyl-Nle17-VIP may be considered useful for the treatment of impotence.",

author = "Illana Gozes and Ayelet Reshef and Dalia Salah and Sara Rubinraut and Mati Fridkin",

year = "1994",

month = may,

doi = "10.1210/en.134.5.2121",

language = "אנגלית",

volume = "134",

pages = "2121--2125",

journal = "Endocrinology",

issn = "0013-7227",

publisher = "Endocrine Society",

number = "5",

}

TY - JOUR

T1 - Stearyl-norleucine-vasoactive intestinal peptide (VIP)

T2 - A novel VIP analog for noninvasive impotence treatment

AU - Gozes, Illana

AU - Reshef, Ayelet

AU - Salah, Dalia

AU - Rubinraut, Sara

AU - Fridkin, Mati

PY - 1994/5

Y1 - 1994/5

N2 - The present report relates to pharmaceutical composition for the treatment of male impotence. The transdermal application of a potent derivative of vasoactive intestinal peptide (VIP) coupled to a suitable hydrophobic moiety (e.g. stearyl-VIP) in a suitable ointment composition (e.g. Sefsol) enhances sexual activity and erection formation in a variety of impotence models in rats (sterile rats, diabetic rats, and animals with high blood pressure). Furthermore, exchange of the methionine in position 17 with norleucine enhances biological activity. Thus, stearyl-Nle17-VIP may be considered useful for the treatment of impotence.

AB - The present report relates to pharmaceutical composition for the treatment of male impotence. The transdermal application of a potent derivative of vasoactive intestinal peptide (VIP) coupled to a suitable hydrophobic moiety (e.g. stearyl-VIP) in a suitable ointment composition (e.g. Sefsol) enhances sexual activity and erection formation in a variety of impotence models in rats (sterile rats, diabetic rats, and animals with high blood pressure). Furthermore, exchange of the methionine in position 17 with norleucine enhances biological activity. Thus, stearyl-Nle17-VIP may be considered useful for the treatment of impotence.

UR - http://www.scopus.com/inward/record.url?scp=0028208932&partnerID=8YFLogxK

U2 - 10.1210/en.134.5.2121

DO - 10.1210/en.134.5.2121

M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???

C2 - 8156912

AN - SCOPUS:0028208932

SN - 0013-7227

VL - 134

SP - 2121

EP - 2125

JO - Endocrinology

JF - Endocrinology

IS - 5

ER -

Stearyl-norleucine-vasoactive intestinal peptide (VIP): A novel VIP analog for noninvasive impotence treatment

Abstract

Access to Document

Other files and links

Fingerprint

Cite this